Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Next Previous
Trial Profile

Open Label Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI)

Completed
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium-difficile-infections; Inflammatory bowel diseases
  • Focus Pharmacokinetics
  • Acronyms PROFILE
  • Sponsors Astellas Pharma Europe Ltd

    • Most Recent Events

    • 14 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 20 Jul 2016 Planned End Date changed from 1 Oct 2017 to 1 Oct 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top